Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00933972 · ClinicalTrials.gov registry record · Phase 1
A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00933972 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 36 participants.
The verdict
NCT00933972, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This 4 arm study will investigate the pharmacodynamics and pharmacokinetics of RO4998452 in type 2 diabetes patients with varying degrees of renal impairment. Eligible patients will be divided into 4 groups, with normal renal function, or mild, moderate or severe renal impairment. All patients will receive a single oral dose of RO4998452 in the fasted state.The anticipated time on study treatment is \<3 months (single dose study)and the target sample size is \<100 individuals.
Interventions
- DRUG RO4998452
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00933972
The ClinicalTrials.gov registry entry for NCT00933972 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO4998452 is the first listed.
NCT00933972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00933972 about?
NCT00933972 is a clinical study titled "A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment". This 4 arm study will investigate the pharmacodynamics and pharmacokinetics of RO4998452 in type 2 diabetes patients with varying degrees of renal impairment. Eligible patients will be divided into 4 groups, with normal renal function, or mild, moderate or severe renal impairment. All patients will ...
What is the current status of trial NCT00933972?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2009-06. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00933972?
The interventions under investigation include: RO4998452 (DRUG).
Who is sponsoring clinical trial NCT00933972?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.